Personalized liposome-based small inhibitory RNA therapy for acute myeloid leukemia (OBS/AML)

ACELLMED Sp. z o.o. and the Silesian Medical Technology Park Kardio-Med Silesia have established cooperation for the implementation of a project co-financed by the European Regional Development Fund under the Regional Operational Programme of the Silesian Voivodeship for 2014-2020 from Priority Axis I. Modern Economy Measure 1.2 Research, Development and Innovation in Enterprises.

The project is named: “Personalized liposome-based small inhibitory RNA therapy for acute myeloid leukemia (OBS/AML).”

PROJECT OBJECTIVE – to develop R&D activity and competitiveness through the implementation of R&D work that will result in a drug that inhibits leukemic cell proliferation used during oncology therapy. The goal will be achieved by June 2023.

The main scientific objective is to develop a targeted, liposome form of miRNA inhibiting the proliferation of cancer cells characterized by selectivity of action, low non-specific, cytotoxicity and high efficiency of nucleic acid delivery to cancer cells, which alone or in combination with standard used cytostatics will significantly improve the effectiveness of treatment. Acellmed and the Silesian Medical Technology Park Kardio-Med Silesia aim to develop a drug that can be used in oncological treatment.

Project objectives:

Delivery time: 52 months

Project value:



    [honeypot honeypot-315]